The iFraP trial recruited over 340 FLS patients to investigate the impact of a decision support tool on osteoporosis person-centred care and medicine uptake.
Join us for a free webinar to hear the trial results. Sign up here🖥️: shorturl.at/9Mq7b
2/2 We also reviewed FLS clinical proforma quality. Most were biomedically focused, didn't guide HCP to ask about fracture symptoms, social circ. or guide info giving. We designed a model (hopefully more holistic) proforma based on findings. @RCP_FFFAPdoi.org/10.21252/r2bw-wz79.
1/2 Latest @iFraP_Study output: UK survey of FLS conduct before & during pandemic
Key findings: > 25% FLSs did not discuss osteoporosis medicines with patients >> missed opportunities for informed decision making #keelemsk@RoyalOsteoPro@NIHRresearchrdcu.be/duYxY
ALT Background and study aims
The iFraP study team have developed a web-based visual tool called a ‘decision-support tool’ to support Fracture Liaison Service (FLS) healthcare professionals to know when to suggest treatments and aid conversations with patients about risk and to make decisions, for instance about starting osteoporosis medicines. The team have also developed training for healthcare professionals to help them use the tool and to ensure that the information they are giving is understandable, that they address patient concerns, and that they give clear, consistent information during the appointment. The decision-support tool and training package together are called the ‘iFraP intervention’. The iFraP study will look at whether the iFraP intervention makes decision-making about osteoporosis medicines easier, and whether it is cost-effective, acceptable and practical to deliver.
ALT Professionals meeting over a changing directions arrow design decision-making concept
Great to be the part of the team to win the Keele University Breaking the Mould award for Social Inclusion tonight alongside my colleague from Expert Citizens and the Keele Impact Accelerator Unit. @KeeleIAU@KeeleUniversity @ExpertCitizens
Qualitative research, a usual care survey (not yet published), the evidence synthesis, and the Delphi all fed into designing iFraP – a decision tool, health professional training package in shared decision making, and additional resources 5/6 bmjopen.bmj.com/content/bmjo…
In feasibility testing, iFraP was well received. We are now conducting a trial to evaluate the clinical and cost effectiveness of iFraP and the impact on patient experience and outcomes. We have recruited 152 people so far… just another 200 ish to go! 6/6 ifrap.co.uk
Really accomplished and powerful presentation from @zpaskins on the power of communication - the myths, messaging and diagnostic muddles around osteoporosis and fractures #osteo2023@RoyalOsteoPro@iFraP_Study
#MPFTCelebrates The iFraP Study 💙
"The team hypothesize their resources will improve patient-centred care and help patients feel more committed and confident in their decisions about taking (or not taking) medicines to lower fracture risk."
Read more below⤵️ #MPFTResearch
📢📰Are you interested in how health appears in the media? Come and join us in developing media recommendations for reporting osteoporosis! Click on the poster below for more details! 📰📢